echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The traditional Chinese medicine sector performed strongly, with 2 more shares up and down

    The traditional Chinese medicine sector performed strongly, with 2 more shares up and down

    • Last Update: 2023-01-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    【Pharmaceutical Network Pharmaceutical Stock Market】On November 24, the traditional Chinese medicine sector performed strongly, and Fangsheng Pharmaceutical and Kangyuan Pharmaceutical both rose to the limit
    .
    Among them, at 10:03 on November 24, Fangsheng Pharmaceutical opened the intraday limit and is now reported at 8.
    96 yuan, with a transaction of 314 million yuan and a turnover rate of 8.
    40%.

    At 10:06 on November 24, Kangyuan Pharmaceutical rose intraday to 25.
    28 yuan, and currently closed 57,307 lots, equivalent to 145 million yuan
    .
    The transaction was 633 million yuan, and the turnover rate was 4.
    58%.

    In addition, Wellcome Pharmaceutical, Guizhou Sanli, Jichuan Pharmaceutical, Yuewan Nianqing, Yiling Pharmaceutical, Tailong Pharmaceutical, Jingjing Pharmaceutical, Hongri Pharmaceutical, Longjin Pharmaceutical, Shouxian Valley, Wanbond, Sunflower Pharmaceutical, etc.
    also rose
    .
    The TCM ETF rose 2.
    41% as of 10:25, gaining momentum
    .
    For the reasons for the recent popularity of the traditional Chinese medicine sector, the analysis believes that it is mainly affected
    by the marginal favorable industry policy.
    It is reported that since the beginning of 2022, the policies of the traditional Chinese medicine sector have continued to be favorable, and policies have been introduced
    one after another.
    For example, on October 14, the "14th Five-Year Plan" for the Development of Chinese Medicine Talents was issued, and the plan mentioned that the goal is: by 2025, the system and mechanism for the development of Chinese medicine talents that meet the characteristics of Chinese medicine will be more perfect, the training and evaluation system will be more reasonable, the scale of talents will grow rapidly, the structural layout will be more reasonable, the growth environment will be significantly optimized, and a team of high-quality Chinese medicine talents will be cultivated and cultivated, providing stronger talent support
    for the revitalization and development of Chinese medicine.
    On September 21, the National Health Commission issued the Notice on Carrying out the Special Activities of Traditional Chinese Medicine Health Promotion in the Healthy China Initiative
    .
    The "Notice" proposed that in the next three years, China will carry out the Healthy China Action TCM health promotion special activities, and it is expected that by 2025, the health management rate of TCM for the elderly over 65 years old will reach 75%, aiming to integrate the concept of TCM into the whole process of health promotion, the whole process of major disease prevention and treatment, and the whole process
    of disease diagnosis and treatment.
    Some time ago, the National Health Commission also issued a notice, clearly emphasizing the unique advantages of traditional Chinese medicine and making a good reserve
    of effective traditional Chinese medicine prescriptions.
    .
    .
    .
    .
    .
    .
    On the whole, the state has frequently introduced policies to support the development of traditional Chinese medicine, and has raised the development plan of traditional Chinese medicine to the national level, in this context, the traditional Chinese medicine industry will usher in more opportunities and achieve better development
    .
    In fact, the traditional Chinese medicine sector has continued to strengthen in recent times, and the industry believes that it is the embodiment
    of benefiting from favorable policies.
    It is reported that on November 14, before the big rise, many stocks such as Jinling Pharmaceutical, Teyi Pharmaceutical, Zhongsheng Pharmaceutical, and Sunflower Pharmaceutical had risen and closed, with Ling Pharmaceutical, Tailong Pharmaceutical, Huluwa, etc.
    rising by more than 7%, and Guizhou Bailing and Huasen Pharmaceutical also followed
    suit.
    On November 9, many stocks such as Teyi Pharmaceutical and Zhongsheng Pharmaceutical also rose to the limit, as well as Yiming Pharmaceutical, Enwei Pharmaceutical, Huluwa, KunYao Group, Dali Pharmaceutical, etc
    .
    At present, the industry is generally optimistic about the long-term development of the traditional Chinese medicine industry and the layout opportunities
    on some subdivisions.
    For example, Zheshang Securities has said that the state attaches great importance to the innovative development of traditional Chinese medicine and the intervention of traditional Chinese medicine in the treatment of pre-existing diseases, and the prevention and treatment of traditional Chinese medicine diseases and health management have become an inevitable development trend, and the traditional Chinese medicine industry has ushered in a new round of development opportunities under the frequent emergence of favorable policies, and it is recommended to pay attention to the investment opportunities
    brought by the formula granule track and the reform of state-owned enterprises 。 Huatai Securities also said that it is optimistic about the growth of consumer traditional Chinese medicine in the long term, and optimistic about the structural opportunities of consumer traditional Chinese medicine in the short and medium term, that is, products with strong brand power and excellent efficacy, are expected to outperform the market through three types of paths: operation improvement, product price increase, and equity incentive under the increase of pharmacy chain rate, decentralization of publicity media, and the
    rise of e-commerce platforms.
    Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
    to anyone.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.